Werkgroep Cardiologische centra Nederland

ODYSSEY (Completed)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients who have Recently Experienced an Acute Coronary Syndrome.
Medicine
alirocumab
Population
ASCVD
Phase
III
Starting year
2012
More information
ClinicalTrials.gov

Director of Study

dr. G.L. Bartels (Cardioloog)
Groningen, Martini Ziekenhuis

Publications: ODYSSEY

  • Alirocumab and Cardiovascular Outcomes after Acute Coronary SyndromeNEJM - ODYSSEY - ASCVD
  • Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial.J Am Coll Cardiol - Abstract - Alings, dr. A.M.W. - ODYSSEY - ASCVD

Publications by WCN study

Publications WCN studies by WCN member